JKJacqueline Kiewa

Jacqueline Kiewa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jacqueline Kiewa has a total of 137 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Poor mood after oral contraceptive use is associated with increased vulnerability to peripartum depression, premenstrual dysphoric disorder, and higher genetic risk for depression

    by Jacqueline Kiewa, Penelope A. Lind, Ian B. Hickie, Sarah E. Medland, Brittany E. Mitchell, Christel M. Middeldorp, Nicholas G. Martin, Naomi R. Wray, Enda M. Byrne

    Purpose: This study tested whether adverse mood effect of the oral contraceptive pill (OCP) is associated with reproductive depressive episodes, including peripartum depression (PPD), premenstrual dysphoric disorder (PMDD), and perimenopausal depression. Method: In a sample of 3,547 OCP users from the Australian Genetics of Depression Study, who reported a lifetime depression diagnosis, logistic regression was used to test the association of PPD, PMDD, and perimenopausal depression with OCP adverse mood effect. Polygenic scores (PGS) for major depression (MD) were also tested for association with adverse mood effect. Sensitivity analyses tested for modification of these associations by a history of depression prior to first OCP use (prior depression), or by depression onset before the age of twenty (child/teen depression onset). Results: Adverse mood effect was reported by 1,342 OCP users (38%). PPD, PMDD, prior depression and child/teen depression onset were significantly associated with adverse mood effect (PPD: Relative Risk (RR) = 1.66,CI=[1.4–2.0], P = 2.0 × 10 − 6 ; PMDD: RR = 3.78,CI=[2.4-6.0], P = 2.2 × 10 − 8 ; prior depression: RR = 1.32,CI=[1.1–1.5], P = 5.9 × 10 − 4 ; child/teen depression onset: RR = 1.56,CI=[1.3–1.8], P = 1.1 × 10 − 7 ). The association of PPD with adverse mood effect remained significant for women with no prior or child/teen depression onset (RR = 1.77,CI=[1.3–2.4], P = 4.6 × 10 − 4 ), but was not significant for women with both prior and child/teen depression onset. Adverse mood effect was significantly associated with PGS for MD: full sample: RR = 1.18,CI=[1.1–1.3], P = 3.6 × 10 − 5 ); no prior or child/teen depression onset: RR = 1.27,CI=[1.1–1.4], P = 3.1 × 10 − 4 . Conclusions: Participants who experience an adverse mood effect with OCP use are likely to have higher genetic vulnerability for depression, and experience child/teen depression onset, as well as reproductive depressive episodes such as PPD.


  • Open Access

    Psychiatric polygenic profiles characterize difficult-to-treat depression versus antidepressant responders in the AGDS:Cell-o cohort

    by Bl Mitchell, D Gilroy, LA Wallace, J Kiewa, R Parker, L Nunn, A Walker, T Lin, L Ziser, G English, et al.

    Purpose Major depressive disorder (MDD) is recognised to be phenotypically heterogeneous, yet subtyping based on clinical features has remained elusive. Here, we investigate heterogeneity by antidepressant-usage according to prescription records. We describe a new cohort, the Cell-omics Resource of the Australian Genetics of Depression Study (AGDS:Cell-o), established to allow integration of individual differences in symptom and genetic profiles with cell-based assays. Participants The study participants had previously enrolled in the AGDS (2016-2019). Briefly, AGDS recruited 22,263 people who self-identified as having lifetime depression. Participants completed detailed online questionnaires (445 questions) which allowed diagnosis of lifetime MDD and characterisation of many other sociodemographic and clinical factors.14,471 AGDS participants consented to linkage with prescription data (Australian Pharmaceutical Benefits Scheme; 4.5 years July 2013–December 2017). These participants were allocated to one of seven mutually exclusive groups based on their monthly prescription patterns. Four groups were defined based on sustained use of specific antidepressants: sertraline, escitalopram or citalopram, desvenlafaxine or venlafaxine, duloxetine. Two groups represent more difficult-to-treat depression (DTD) where participants showed no sustained dispensing of a single antidepressant: one was defined by self-reported treatment (or recommended treatment) with electro-convulsive therapy and the other by augmentation of antidepressants with either lithium or antipsychotics. The seventh group had self-reported diagnosis of bipolar disorder as well as prescription history of lithium. In 2023-2025 a subset of AGDS participants were invited to enrol in AGDS:Cell-o selected based on their antidepressant group membership. Participants were blinded to their group assignment and, if they consented to participate, completed detailed questionnaires about their symptoms, how medication changed their symptoms, and medication side effects. Findings to date Of 9,965 AGDS participants with an MDD diagnosis, at least one prescription record of antidepressants, genome-wide genotype data and of inferred European ancestry, 5,762 (58%) could be allocated to one of the seven antidepressant use groups. Of 3,107 people invited to view our AGDS:Cell-o website, 713 consented to participate in the study (to date). The self-reported antidepressant usage of these participants were compared to their prescription group; there was good consistency despite there being ∼7 years between the prescription records used to make the groups and recruitment into AGDS:Cello. This is an interim report based on questionnaire data available to July 31 2025; the report will be updated when the study recruitment is closed (October 1 2025). Future plans Participants provided blood samples which were processed to harvest peripheral blood mononuclear cells (PBMCs) to allow lymphoblastoid cell line (LCL), induced pluripotent stem cell (iPSC), assembloid or organoid studies. We plan to collect cell-based biological measures representing the genomes of AGDS:Cell-o participants which can be associated with a breadth of self-reported measures collected in the AGDS baseline and follow-up questionnaires and the AGDS:Cell-o questionnaire.


  • Open Access

    Comprehensive Sex-Stratified Genetic Analysis of 28 Blood Biomarkers and Depression Reveals a Significant Association between Depression and Low Levels of Total Protein in Females

    by Jacqueline Kiewa, Samantha Meltzer-Brody, Jeannette Milgrom, Jerry Guintivano, Ian B. Hickie, David C. Whiteman, Catherine M. Olsen, Sarah E. Medland, Nicholas G. Martin, Naomi R. Wray, et al.

    Introduction: Major depression (MD) is more common amongst women than men, and MD episodes have been associated with fluctuations in reproductive hormones amongst women. To investigate biological underpinnings of heterogeneity in MD, the associations between depression, stratified by sex and including perinatal depression (PND), and blood biomarkers, using UK Biobank (UKB) data, were evaluated, and extended to include the association of depression with biomarker polygenic scores (PGS), generated as proxy for each biomarker. Method: Using female (N = 39,761) and male (N = 38,821) UKB participants, lifetime MD and PND were tested for association with 28 blood biomarkers. A GWAS was conducted for each biomarker and genetic correlations with depression subgroups were estimated. Using independent data from the Australian Genetics of Depression Study, PGS were constructed for each biomarker, and tested for association with depression status (n [female cases/controls] = 9,006/6,442; n [male cases/controls] = 3,106/6,222). Regions of significant local genetic correlation between depression subgroups and biomarkers highlighted by the PGS analysis were identified. Results: Depression in females was significantly associated with levels of twelve biomarkers, including total protein (OR = 0.90, CI = [0.86, 0.94], p = 3.9 × 10−6) and vitamin D (OR = 0.94, CI = [0.90, 0.97], p = 2.6 × 10−4), and PND with five biomarker levels, also including total protein (OR = 0.88, CI = [0.81, 0.96], p = 4.7 × 10−3). Depression in males was significantly associated with levels of eleven biomarkers. In the independent Australian Genetics of Depression Study, PGS analysis found significant associations for female depression and PND with total protein (female depression: OR = 0.93, CI = [0.88, 0.98], p = 3.6 × 10−3; PND: OR = 0.91, CI = [0.86, 0.96], p = 1.1 × 10−3), as well as with vitamin D (female depression: OR = 0.93, CI = [0.89, 0.97], p = 2.0 × 10−3; PND: OR = 0.92, CI = [0.87, 0.97], p = 1.4 × 10−3). The male depression sample did not report any significant results, and the point estimate of total protein (OR = 0.98, CI = [0.92–1.04], p = 4.7 × 10−1) did not indicate any association. Local genetic correlation analysis highlighted significant genetic correlation between PND and total protein, located in 5q13.3 (rG = 0.68, CI = [0.33, 1.0], p = 3.6 × 10−4). Discussion and Conclusion: Multiple lines of evidence from genetic analysis highlight an association between total serum protein levels and depression in females. Further research involving prospective measurement of total protein and depressive symptoms is warranted.


  • Top Cited Papers
    Open Access

    Meta-Analyses of Genome-Wide Association Studies for Postpartum Depression

    by Jerry Guintivano, Enda M. Byrne, Jacqueline Kiewa, Shuyang Yao, Anna E. Bauer, Karolina A. Aberg, Mark J. Adams, Archie Campbell, Megan L. Campbell, Karmel W. Choi, et al.

    Objective: Postpartum depression (PPD) is a common subtype of major depressive disorder (MDD) that is more heritable, yet is understudied in psychiatric genetics. The authors conducted meta-analyses of genome-wide association studies (GWASs) to investigate the genetic architecture of PPD. Method: Meta-analyses were conducted on 18 cohorts of European ancestry (17,339 PPD cases and 53,426 controls), one cohort of East Asian ancestry (975 cases and 3,780 controls), and one cohort of African ancestry (456 cases and 1,255 controls), totaling 18,770 PPD cases and 58,461 controls. Post-GWAS analyses included 1) single-nucleotide polymorphism (SNP)–based heritability , 2) genetic correlations between PPD and other phenotypes, and 3) enrichment of the PPD GWAS findings in 27 human tissues and 265 cell types from the mouse central and peripheral nervous system. Results: No SNP achieved genome-wide significance in the European or the trans-ancestry meta-analyses. The of PPD was 0.14 (SE=0.02). Significant genetic correlations were estimated for PPD with MDD, bipolar disorder, anxiety disorders, posttraumatic stress disorder, insomnia, age at menarche, and polycystic ovary syndrome. Cell-type enrichment analyses implicate inhibitory neurons in the thalamus and cholinergic neurons within septal nuclei of the hypothalamus, a pattern that differs from MDD. Conclusions: While more samples are needed to reach genome-wide levels of significance, the results presented confirm PPD as a polygenic and heritable phenotype. There is also evidence that despite a high correlation with MDD, PPD may have unique genetic components. Cell enrichment results suggest GABAergic neurons, which converge on a common mechanism with the only medication approved by the U.S. Food and Drug Administration for PPD (brexanolone).


  • Open Access

    A Common Genetic Factor Underlies Genetic Risk for Gynaecological and Reproductive Disorders and Is Correlated with Risk to Depression

    by Jacqueline Kiewa, Sally Mortlock, Samantha Meltzer-Brody, Christel Middeldorp, Naomi R. Wray, Enda M. Byrne

    Introduction: Sex steroid hormone fluctuations may underlie both reproductive disorders and sex differences in lifetime depression prevalence. Previous studies report high comorbidity among reproductive disorders and between reproductive disorders and depression. This study sought to assess the multivariate genetic architecture of reproductive disorders and their loading onto a common genetic factor and investigated whether this latent factor shares a common genetic architecture with female depression, including perinatal depression (PND). Method: Using UK Biobank and FinnGen data, genome-wide association meta-analyses were conducted for nine reproductive disorders, and genetic correlation between disorders was estimated. Genomic Structural Equation Modelling identified a latent genetic factor underlying disorders, accounting for their significant genetic correlations. SNPs significantly associated with both latent factor and depression were identified. Results: Excellent model fit existed between a latent factor underlying five reproductive disorders (χ2 (5) = 6.4; AIC = 26.4; CFI = 1.00; SRMR = 0.03) with high standardised loadings for menorrhagia (0.96, SE = 0.05); ovarian cysts (0.94, SE = 0.05); endometriosis (0.83, SE = 0.05); menopausal symptoms (0.77, SE = 0.10); and uterine fibroids (0.65, SE = 0.05). This latent factor was genetically correlated with PND (rG = 0.37, SE = 0.15, p = 1.4e−03), depression in females only (rG = 0.48, SE = 0.06, p = 7.2e−11), and depression in both males and females (MD) (rG = 0.35, SE = 0.03, p = 1.8e−30), with its top locus associated with FSHB/ARL14EP (rs11031006; p = 9.1e−33). SNPs intronic to ESR1, significantly associated with the latent factor, were also associated with PND, female depression, and MD. Conclusion: A common genetic factor, correlated with depression, underlies risk of reproductive disorders, with implications for aetiology and treatment. Genetic variation in ESR1 is associated with reproductive disorders and depression, highlighting the importance of oestrogen signalling for both reproductive and mental health.


  • The genomics of perinatal depression

    by Jacqueline Kiewa

    The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.

  • Open Access

    Lifetime prevalence and correlates of perinatal depression in a case-cohort study of depression

    by Jacqueline Kiewa, Samantha Meltzer-Brody, Jeannette Milgrom, Elizabeth Bennett, Tracey Mackle, Jerry Guintivano, Ian B Hickie, Lucia Colodro-Conde, Sarah E Medland, Nick Martin, et al.

    Objectives This study sought to evaluate the prevalence, timing of onset and duration of symptoms of depression in the perinatal period (PND) in women with depression, according to whether they had a history of depression prior to their first perinatal period. We further sought to identify biopsychosocial correlates of perinatal symptoms in women with depression. Design and setting The Australian Genetics of Depression Study is an online case cohort study of the aetiology of depression. For a range of variables, women with depression who report significant perinatal depressive symptoms were compared with women with lifetime depression who did not experience perinatal symptoms. Participants In a large sample of parous women with major depressive disorder (n=7182), we identified two subgroups of PND cases with and without prior depression history (n=2261; n=878, respectively). Primary and secondary outcome measures The primary outcome measure was a positive screen for PND on the lifetime version of the Edinburgh Postnatal Depression Scale. Descriptive measures reported lifetime prevalence, timing of onset and duration of PND symptoms. There were no secondary outcome measures. Results The prevalence of PND among parous women was 70%. The majority of women reported at least one perinatal episode with symptoms both antenatally and postnatally. Of women who experienced depression prior to first pregnancy, PND cases were significantly more likely to report more episodes of depression (OR=1.15 per additional depression episode, 95% CI 1.13 to 1.17, pConclusions The majority of parous women with lifetime depression in this study experienced PND, associated with more complex, severe depression. Results highlight the importance of perinatal assessments of depressive symptoms, particularly for women with a history of depression or childhood adverse experiences.


  • Perinatal depression is associated with a higher polygenic risk for major depressive disorder than non‐perinatal depression

    by Jacqueline Kiewa, Samantha Meltzer‐Brody, Jeanette Milgrom, Jerry Guintivano, Ian B. Hickie, David C. Whiteman, Catherine M. Olsen, Lucía Colodro‐Conde, Sarah E. Medland, Nicholas G. Martin, et al.

    Background Distinctions between major depressive disorder (MDD) and perinatal depression (PND) reflect varying views of PND, from a unique etiological subtype of MDD to an MDD episode that happens to coincide with childbirth. This case–control study investigated genetic differences between PND and MDD outside the perinatal period (non-perinatal depression or NPD). Methods We conducted a genome-wide association study using PND cases (Edinburgh Postnatal Depression Scale score ≥ 13) from the Australian Genetics of Depression Study 2018 data (n = 3804) and screened controls (n = 6134). Results of gene-set enrichment analysis were compared with those of women with non-PND. For six psychiatric disorders/traits, genetic correlations with PND were evaluated, and logistic regression analysis reported polygenic score (PGS) association with both PND and NPD. Results Genes differentially expressed in ovarian tissue were significantly enriched (stdBeta = 0.07, p = 3.3e−04), but were not found to be associated with NPD. The genetic correlation between PND and MDD was 0.93 (SE = 0.07; p = 3.5e−38). Compared with controls, PGS for MDD are higher for PND cases (odds ratio [OR] = 1.8, confidence interval [CI] = [1.7–1.8], p = 9.5e−140) than for NPD cases (OR = 1.6, CI = [1.5–1.7], p = 1.2e−49). Highest risk is for those reporting both antenatal and postnatal depression, irrespective of prior MDD history. Conclusions PND has a high genetic overlap with MDD, but points of distinction focus on differential expression in ovarian tissue and higher MDD PGS, particularly for women experiencing both antenatal and postpartum PND.


  • Open Access

    Lifetime Prevalence and Risk Factors for Perinatal Depression in a Large Cohort of Women with Depression

    by Jacqueline Kiewa, Samantha Meltzer-Brody, Jeanette Milgrom, Elizabeth Bennett, Tracey Mackle, Jerry Guintivano, Ian B Hickie, Lucía Colodro-Conde, Sarah Medland, Nicholas G Martin, et al.

    ObjectivesAmongst women with a history of depression, this study sought to identify risk factors associated with reporting perinatal depression (PND)). Lifetime prevalence, length and severity of PND were evaluated, as well as the effect of PND onset either after previous depression episodes, or as the first episode of depression.SettingThe Australian Genetics of Depression Study (AGDS), an online case cohort study of the etiology of depression.ParticipantsIn a large sample of parous women who met DSM criteria for major depressive disorder (MDD) (n=7,182), we identified two subgroups of PND cases (Edinburgh Postnatal Depression Scale score >= 13) with and without prior depression history (n=2,261; n=878 respectively). For a range of risk factors, both subgroups were compared to women with MDD who did not report depressive symptoms in the perinatal period (non-perinatal depression (NPD) cases). PND cases with prior depression history were compared to NPD cases with depression onset before their first pregnancy (n=672). PND cases without prior depression history were compared to all NPD cases (n=2,124).Primary and secondary outcome measuresDescriptive measures reported lifetime prevalence, length, and severity of PND. Logistic regression compared a range of characteristics of PND cases to those of the comparison group of NPD cases.ResultsOf women who experienced depression prior to first pregnancy, PND cases were significantly more likely to report more episodes of depression (OR=1.1 per additional depression episode, CI=[1.1-1.1], P=1.9e-13), non-European ancestry (OR=1.5, CI=[1.0-2.1], P=3.4e-02), severe nausea during pregnancy (OR=1.3, CI=[1.1-1.6], P=6.6e-03) and emotional abuse (OR=1.4, CI=[1.1-1.7], P=5.3e-03). Women without any depression before their first perinatal episode were significantly more likely to report emotional abuse (OR=1.3, CI=[1.1-1.6], P=1.0e-02) than women with NPD.ConclusionsThe majority of parous women in this study experienced PND, associated with more complex, severe depression. Results highlight the importance of perinatal assessments of depressive symptoms, particularly for women with a history of depression or childhood adverse experiences.